Literature DB >> 31140920

Risk Factors for Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Carriage in Patients Admitted to Intensive Care Unit in a Tertiary Care Hospital in Thailand.

Anong Kiddee1, Kanit Assawatheptawee1, Anamai Na-Udom2, Pratya Boonsawang1, Pornpit Treebupachatsakul3, Timothy R Walsh4, Pannika R Niumsup1,5.   

Abstract

Extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-PE) are important causes of serious infections in intensive care unit (ICU). This study aimed to investigate the risk factors for intestinal carriage of ESBL-PE among patients admitted to ICU, subsequent ESBL-PE infections, and outcomes of these patients. This study prospectively collected rectal swabs from 215 ICU patients in Northern Thailand and ESBL-PE were isolated. A high prevalence of ESBL-PE carriage (134/215, 62.3%) at ICU admission was observed, with Escherichia coli representing the predominant organism (67.5%) followed by Klebsiella pneumoniae (19.4%). Multivariate logistic regression analysis identified chronic renal disease as the independent risk factor for ESBL-PE carriage (p = 0.009; adjusted odds ratio = 4.369; 95% confidence interval = 1.455-13.119). Among colonized patients, 2.2% (3/134) developed ESBL-PE infections during ICU stay. Phylogenetic analysis of E. coli (n = 108) showed that the predominant group was group A (38.0%), followed by groups B1 (17.6%), D (15.7%), B2 (14.8%), C (7.4%), and F (6.5%). Multilocus sequence typing analysis of the pathogenic groups B2, D, and F revealed 11 different sequence types (STs), with ST131 (n = 13) as the most prevalent, followed by ST648 (n = 5), ST38 (n = 4), ST393 (n = 3), and ST1193 (n = 3). These results are of concern since ESBL-PE may be a prerequisite for endogenous infections and potentially disseminate within the hospital. This is the first study describing ESBL-PE carriage among patients at ICU admission and subsequent ESBL-PE infections in Thailand.

Entities:  

Keywords:  ESBL; Enterobacteriaceae; ICU; ST131; carriage

Mesh:

Substances:

Year:  2019        PMID: 31140920     DOI: 10.1089/mdr.2018.0318

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN: 1076-6294            Impact factor:   3.431


  5 in total

Review 1.  Escherichia coli ST1193: Following in the Footsteps of E. coli ST131.

Authors:  Johann D D Pitout; Gisele Peirano; Liang Chen; Rebekah DeVinney; Yasufumi Matsumura
Journal:  Antimicrob Agents Chemother       Date:  2022-06-06       Impact factor: 5.938

Review 2.  Comparison of the global prevalence and trend of human intestinal carriage of ESBL-producing Escherichia coli between healthcare and community settings: a systematic review and meta-analysis.

Authors:  Yihienew M Bezabih; Alemayehu Bezabih; Michel Dion; Eric Batard; Samson Teka; Abiy Obole; Noah Dessalegn; Alelegn Enyew; Anna Roujeinikova; Endalkachew Alamneh; Corinne Mirkazemi; Gregory M Peterson; Woldesellassie M Bezabhe
Journal:  JAC Antimicrob Resist       Date:  2022-06-02

3.  Molecular Epidemiology of and Risk Factors for Extensively Drug-Resistant Klebsiella pneumoniae Infections in Southwestern China: A Retrospective Study.

Authors:  Xiaolang Tian; Changwu Huang; Xiaoli Ye; Hongyan Jiang; Rufang Zhang; Xiaofang Hu; Dongshuang Xu
Journal:  Front Pharmacol       Date:  2019-11-01       Impact factor: 5.810

4.  Prevalence and risk factors associated with multi-drug resistant organisms (MDRO) carriage among pediatric patients at the time of admission in a tertiary care hospital of a developing country. A cross-sectional study.

Authors:  Sonia Qureshi; Noshi Maria; Mohammad Zeeshan; Seema Irfan; Farah Naz Qamar
Journal:  BMC Infect Dis       Date:  2021-06-09       Impact factor: 3.090

Review 5.  Epidemiology of Extended-Spectrum Beta-Lactamase and Carbapenemase-Producing Enterobacterales in the Greater Mekong Subregion: A Systematic-Review and Meta-Analysis of Risk Factors Associated With Extended-Spectrum Beta-Lactamase and Carbapenemase Isolation.

Authors:  Shweta R Singh; Alvin Kuo Jing Teo; Kiesha Prem; Rick Twee-Hee Ong; Elizabeth A Ashley; H Rogier van Doorn; Direk Limmathurotsakul; Paul Turner; Li Yang Hsu
Journal:  Front Microbiol       Date:  2021-11-26       Impact factor: 5.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.